Barry Wohl

Barry Wohl has a varied work experience in the healthcare industry. Barry started their career in 2008 at Medtronic, where they worked as a Senior Clinical Research Specialist and R&D Design Engineer until 2012. Barry then joined Biogen Idec in 2013, where they worked in Corporate Strategy and Portfolio Management. In 2014, they moved on to IMS Consulting Group, working as a Strategy and Management Consultant. In 2015, they joined Symbal Therapeutics as Chief Business Officer. Barry then worked as Senior Director of Alliance Management at Macrolide Pharma (now Zikani Therapeutics) from 2017 to 2018. Currently, they serve as the Chief Business Officer at Apnimed since June 2018.

Barry Wohl has pursued their education at various prestigious institutions. Barry holds a Bachelor of Science (BS) degree in Biomedical Engineering from Columbia University. Continuing their academic journey, Barry also obtained a Master of Science (MS) degree in Mechanical Engineering from Stanford University. Additionally, they have studied at Harvard Business School, where they earned a Master of Business Administration (MBA) degree. Although specific start and end years for each program are not provided, Barry's education history showcases their dedication and diverse expertise in multiple fields.